IP Library Granted Patent US 8,389,678
Granted Patent B2
US 8,389,678 · App. 13/418,567 · Granted Mar 5, 2013

Protein fragments of virB10 and sero-detection of

Inventors: John G. Hoey (Elmer, NJ); Denise P. Dimitrov (Marlton, NJ); Lisa B. Huang (Princeton, NJ); Martin E. Adelson (Belle Mead, NJ); Eli Mordechai (Robbinsville, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,678
App. No.
13/418,567
Granted
Mar 5, 2013
Kind
B2
Abstract

Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum . Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.

Claims (14)

1. An isolated polypeptide, wherein said isolated polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NO: 13 and SEQ ID NO: 15.

2. The isolated polypeptide of claim 1 , wherein said isolated polypeptide consists of the amino acid sequence of SEQ ID NO: 13.

3. The isolated polypeptide of claim 1 , wherein said isolated polypeptide consists of the amino acid sequence of SEQ ID NO: 15.

4. A composition comprising the isolated polypeptide of claim 1 and an inert support.

5. The composition of claim 4 , wherein said inert support is selected from the group consisting of polyethylene, polypropylene and glass.

6. The composition of claim 4 , wherein said inert support is a microtiter well.

7. An article of manufacture comprising a packaging material and the isolated polypeptide of claim 1 .

8. The article of manufacture of claim 7 , wherein said packaging material comprises an instruction for detecting the presence of antibody against Anaplasma phagocytophilum .

9. A method of producing the isolated polypeptide of claim 1 , comprising the steps of:

(i) introducing an isolated polynucleotide into a host cell, wherein said isolated polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO. 12 and SEQ ID NO: 14;

(ii) growing said host cell in a culture medium under suitable conditions to permit production of said polypeptide and

(iii) isolating said isolated polypeptide.

10. The method of claim 9 , wherein said polynucleotide has the nucleotide sequence set forth in SEQ ID NO: 12 and said isolated polypeptide consists of the amino acid set forth in SEQ ID NO: 13.

11. The method of claim 9 , wherein said polynucleotide has the nucleotide sequence set forth in SEQ ID NO: 14 and said isolated polypeptide consists of the amino acid set forth in SEQ ID NO: 15.

Assignments (4)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (3)
Division 12658506 · Feb 9, 2010
Provisional Application 61208761 · Feb 27, 2009
Related Publication 20120183979A1 · Jul 19, 2012